Satellos Bioscience (NASDAQ:MSLE – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a note issued to investors on Saturday, Wall Street Zen reports.
Several other brokerages also recently commented on MSLE. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Satellos Bioscience in a research report on Wednesday, November 4th. Craig Hallum began coverage on Satellos Bioscience in a research note on Thursday, October 8th. They issued a “buy” rating and a $24.00 target price on the stock. Zacks Research downgraded Satellos Bioscience from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 21st. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Satellos Bioscience in a research note on Monday, August 17th. Six analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, Satellos Bioscience has an average rating of “Moderate Buy” and a consensus price target of $20.60.
Check Out Our Latest Stock Analysis on Satellos Bioscience
Satellos Bioscience Stock Performance
Shares of NASDAQ MSLE opened at $6.63 on Friday. The business’s 50 day moving average price is $7.77 and its 200-day moving average price is $8.19. Satellos Bioscience has a fifty-two week low of $5.30 and a fifty-two week high of $13.39. The company has a market cap of $140.69 million, a price-to-earnings ratio of -3.17 and a beta of 1.63.
Satellos Bioscience (NASDAQ:MSLE – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.09). Sell-side analysts predict that Satellos Bioscience will post -1.86 earnings per share for the current year.
Hedge Funds Weigh In On Satellos Bioscience
A hedge fund recently raised its position in Satellos Bioscience stock. AWM Investment Company Inc. grew its stake in shares of Satellos Bioscience Inc. (NASDAQ:MSLE – Free Report) by 41.9% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 305,000 shares of the company’s stock after acquiring an additional 90,000 shares during the period. AWM Investment Company Inc. owned about 1.46% of Satellos Bioscience worth $2,338,000 at the end of the most recent quarter.
Satellos Bioscience Company Profile
Satellos Bioscience is a biotechnology company developing treatments intended to improve the body’s ability to repair and regenerate muscle. Its research focuses on muscle stem cells and the cellular processes that guide their function. The company’s lead program, SAT-3247, is an investigational oral small-molecule therapy being developed for Duchenne muscular dystrophy. Satellos is studying whether its approach can restore muscle stem-cell activity and support muscle regeneration; the candidate remains in development and is not an approved treatment.
See Also
- Five stocks we like better than Satellos Bioscience
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Satellos Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Satellos Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
